Contribution of the environment and comorbidities to chronic obstructive pulmonary disease phenotypes

Medical Clinics of North America

Volumn 96, Issue 4, 2012, Pages 713-727

  Martinez, Carlos H ^a   Han, MeiLan K ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Chronic bronchitis; Emphysema; Inflammation; Systemic disease

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUEL; GROWTH HORMONE RELEASING FACTOR; HOST FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; PLACEBO; PREDNISONE; ROFLUMILAST; STEROID; VITAMIN D;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANEMIA; ANXIETY DISORDER; ASTHMA; ATHEROSCLEROSIS; BACTERIAL COLONIZATION; BIOMASS; BONE DENSITOMETRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREAL; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COAL MINING; COGNITIVE DEFECT; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; COOKING; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG WITHDRAWAL; DUST EXPOSURE; DYSPHAGIA; DYSPNEA; EMPHYSEMA; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPIGENETICS; EXERCISE; FORCED EXPIRATORY VOLUME; FUME; GAS; GASTROESOPHAGEAL REFLUX; GENETIC ASSOCIATION; GENETIC RISK; GROWTH HORMONE DEFICIENCY; HEARTBURN; HUMAN; HYPERCAPNIA; HYPERMETABOLISM; HYPOXEMIA; INFLAMMATION; LUNG EMPHYSEMA; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MORTALITY; OCCUPATIONAL EXPOSURE; OSTEOPOROSIS; OXIDATIVE STRESS; PASSIVE SMOKING; PATHOGENESIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY REHABILITATION; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SLEEP APNEA SYNDROME; SMOKING; SMOKING CESSATION; TOBACCO; TUBERCULOSIS; VAPOR; VERTEBRA FRACTURE; VITAMIN BLOOD LEVEL;

ANEMIA; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; DISEASE PROGRESSION; ENVIRONMENT; GASTROESOPHAGEAL REFLUX; HUMANS; MENTAL DISORDERS; MUSCULOSKELETAL DISEASES; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE;

EID: 84863825223     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.02.007     Document Type: Review

References (105)

1. Agusti A., Calverley P.M., Celli B., et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010, 11:122.
2. Han M.K., Agusti A., Calverley P.M., et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010, 182:598-604.
3. Lokke A., Lange P., Scharling H., et al. Developing COPD: a 25 year follow up study of the general population. Thorax 2006, 61:935-939.
4. Anthonisen N.R., Connett J.E., Kiley J.P., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994, 272:1497-1505.
5. Eisner M.D., Balmes J., Katz P.P., et al. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ Health 2005, 4:7.
6. Behrendt C.E. Mild and moderate-to-severe COPD in nonsmokers: distinct demographic profiles. Chest 2005, 128:1239-1244.
7. Salvi S.S., Barnes P.J. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009, 374:733-743.
8. Lamprecht B., McBurnie M.A., Vollmer W.M., et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 2011, 139:752-763.
9. Silva G.E., Sherrill D.L., Guerra S., et al. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004, 126:59-65.
10. Shavelle R.M., Paculdo D.R., Kush S.J., et al. Life expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III Follow-up Study. Int J Chron Obstruct Pulmon Dis 2009, 4:137-148.
11. Blanc P.D., Eisner M.D., Earnest G., et al. Further exploration of the links between occupational exposure and chronic obstructive pulmonary disease. J Occup Environ Med 2009, 51:804-810.
12. Fairbairn A.S., Reid D.D. Air pollution and other local factors in respiratory disease. Br J Prev Soc Med 1958, 12:94-103.
13. Andersen Z.J., Hvidberg M., Jensen S.S., et al. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. Am J Respir Crit Care Med 2011, 183:455-461.
14. Han M.K., Postma D., Mannino D.M., et al. Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med 2007, 176:1179-1184.
15. Ramirez-Venegas A., Sansores R.H., Perez-Padilla R., et al. Survival of patients with chronic obstructive pulmonary disease due to biomass smoke and tobacco. Am J Respir Crit Care Med 2006, 173:393-397.
16. Janssens W., Lehouck A., Carremans C., et al. Vitamin D beyond bones in chronic obstructive pulmonary disease: time to act. Am J Respir Crit Care Med 2009, 179:630-636.
17. Wood A.M., Bassford C., Webster D., et al. Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax 2011, 66:205-210.
18. Sargeant L.A., Jaeckel A., Wareham N.J. Interaction of vitamin C with the relation between smoking and obstructive airways disease in EPIC Norfolk. European prospective investigation into cancer and nutrition. Eur Respir J 2000, 16:397-403.
19. Hirayama F., Lee A.H., Binns C.W., et al. Do vegetables and fruits reduce the risk of chronic obstructive pulmonary disease? A case-control study in Japan. Prev Med 2009, 49:184-189.
20. Varraso R., Willett W.C., Camargo C.A. Prospective study of dietary fiber and risk of chronic obstructive pulmonary disease among US women and men. Am J Epidemiol 2010, 171:776-784.
21. Watson L., Vestbo J., Postma D.S., et al. Gender differences in the management and experience of chronic obstructive pulmonary disease. Respir Med 2004, 98:1207-1213.
22. Martinez F.J., Curtis J.L., Sciurba F., et al. Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med 2007, 176:243-252.
23. Hurst J.R., Vestbo J., Anzueto A., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
24. Tashkin D., Celli B., Kesten S., et al. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir Med 2010, 104:1495-1504.
25. Bjorksten B., Sepp E., Julge K., et al. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001, 108:516-520.
26. Kalliomaki M., Kirjavainen P., Eerola E., et al. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001, 107:129-134.
27. Penders J., Thijs C., van den Brandt P.A., et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut 2007, 56:661-667.
28. Martinez F., Han M., Flaherty K., et al. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Anti Infect Ther 2006, 4:101-124.
29. Sethi S., Murphy T. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008, 359:2355-2365.
30. Erb-Downward J.R., Thompson D.L., Han M.K., et al. Analysis of the lung microbiome in the " healthy" smoker and in COPD. PLoS One 2011, 6:e16384.
31. Marin J.M., Soriano J.B., Carrizo S.J., et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010, 182:325-331.
32. Agusti A.G., Noguera A., Sauleda J., et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:347-360.
33. Fabbri L.M., Rabe K.F. From COPD to chronic systemic inflammatory syndrome?. Lancet 2007, 370:797-799.
34. Hansell A.L., Walk J.A., Soriano J.B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003, 22:809-814.
35. Sin D.D., Wu L., Man S.F. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005, 127:1952-1959.
36. Anthonisen N.R., Connett J.E., Enright P.L., et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002, 166:333-339.
37. Beaty T.H., Newill C.A., Cohen B.H., et al. Effects of pulmonary function on mortality. J Chronic Dis 1985, 38:703-710.
38. Speizer F.E., Fay M.E., Dockery D.W., et al. Chronic obstructive pulmonary disease mortality in six U.S. cities. Am Rev Respir Dis 1989, 140:S49-S55.
39. Hospers J.J., Postma D.S., Rijcken B., et al. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000, 356:1313-1317.
40. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
41. Han M.K., McLaughlin V.V., Criner G.J., et al. Pulmonary diseases and the heart. Circulation 2007, 116:2992-3005.
42. Sin D.D., Lacy P., York E., et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170:760-765.
43. Mancini G.B., Etminan M., Zhang B., et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006, 47:2554-2560.
44. Soyseth V., Brekke P.H., Smith P., et al. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007, 29:279-283.
45. Short P.M., Lipworth S.I., Elder D.H., et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011, 342:d2549.
46. Chailleux E., Laaban J.P., Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. Chest 2003, 123:1460-1466.
47. Landbo C., Prescott E., Lange P., et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160:1856-1861.
48. Vestbo J., Prescott E., Almdal T., et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006, 173:79-83.
49. Celli B.R., Cote C.G., Marin J.M., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012.
50. Marquez-Martin E., Ramos P.C., Lopez-Campos J.L., et al. Components of physical capacity in patients with chronic obstructive pulmonary disease: relationship with phenotypic expression. Int J Chron Obstruct Pulmon Dis 2011, 6:105-112.
51. Kurosaki H., Ishii T., Motohashi N., et al. Extent of emphysema on HRCT affects loss of fat-free mass and fat mass in COPD. Intern Med 2009, 48:41-48.
52. Kim V., Han M.K., Vance G.B., et al. The chronic bronchitic phenotype of chronic obstructive pulmonary disease: an analysis of the COPDGene Study. Chest 2011, 140(3):626-633.
53. Wagner P.D. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J 2008, 31:492-501.
54. Vogiatzis I., Simoes D.C., Stratakos G., et al. Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD. Eur Respir J 2010, 36:301-310.
55. Nuti R., Siviero P., Maggi S., et al. Vertebral fractures in patients with chronic obstructive pulmonary disease: the EOLO Study. Osteoporos Int 2009, 20:989-998.
56. Bolton C.E., Ionescu A.A., Shiels K.M., et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170:1286-1293.
57. Sin D.D., Man J.P., Man S.F. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003, 114:10-14.
58. Dam T.T., Harrison S., Fink H.A., et al. Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos Int 2010, 21:1341-1349.
59. Bon J., Fuhrman C.R., Weissfeld J.L., et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med 2011, 183:885-890.
60. Bolton C.E., Stone M.D., Edwards P.H., et al. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Chron Respir Dis 2009, 6:81-87.
61. Bon J.M., Leader J.K., Weissfeld J.L., et al. The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PLoS One 2009, 4:e6865.
62. Vondracek S.F., Voelkel N.F., McDermott M.T., et al. The relationship between adipokines, body composition, and bone density in men with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2009, 4:267-277.
63. Beauchamp M.K., O'Hoski S., Goldstein R.S., et al. Effect of pulmonary rehabilitation on balance in persons with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2010, 91:1460-1465.
64. Leone N., Courbon D., Thomas F., et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med 2009, 179:509-516.
65. Song Y., Klevak A., Manson J.E., et al. Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women's Health Study. Diabetes Res Clin Pract 2010, 90:365-371.
66. Lazarus R., Sparrow D., Weiss S.T. Baseline ventilatory function predicts the development of higher levels of fasting insulin and fasting insulin resistance index: the Normative Aging Study. Eur Respir J 1998, 12:641-645.
67. Rana J.S., Mittleman M.A., Sheikh J., et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 2004, 27:2478-2484.
68. Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010, 123:1001-1006.
69. Han M.K., Kazerooni E.A., Lynch D.A., et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene Study: associated radiologic phenotypes. Radiology 2011, 261(1):274-282.
70. Cote C., Zilberberg M.D., Mody S.H., et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007, 29:923-929.
71. Ershler W.B., Chen K., Reyes E.B., et al. Economic burden of patients with anemia in selected diseases. Value Health 2005, 8:629-638.
72. Chambellan A., Chailleux E., Similowski T. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest 2005, 128:1201-1208.
73. John M., Lange A., Hoernig S., et al. Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. Int J Cardiol 2006, 111:365-370.
74. Halpern M.T., Zilberberg M.D., Schmier J.K., et al. Anemia, costs and mortality in chronic obstructive pulmonary disease. Cost Eff Resour Alloc 2006, 4:17.
75. Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
76. Mokhlesi B., Morris A.L., Huang C.F., et al. Increased prevalence of gastroesophageal reflux symptoms in patients with COPD. Chest 2001, 119:1043-1048.
77. Terada K., Muro S., Sato S., et al. Impact of gastrooesophageal reflux disease symptoms on COPD exacerbation. Thorax 2008, 63:951-955.
78. Casanova C., Baudet J.S., del Valle Velasco M., et al. Increased gastrooesophageal reflux disease in patients with severe COPD. Eur Respir J 2004, 23:841-845.
79. Rascon-Aguilar I.E., Pamer M., Wludyka P., et al. Poorly treated or unrecognized GERD reduces quality of life in patients with COPD. Dig Dis Sci 2011, 56:1976-1980.
80. Rascon-Aguilar I.E., Pamer M., Wludyka P., et al. Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest 2006, 130:1096-1101.
81. Terada K., Muro S., Ohara T., et al. Abnormal swallowing reflex and COPD exacerbations. Chest 2010, 137:326-332.
82. Garcia Rodriguez L.A., Ruigomez A., Martin-Merino E., et al. Relationship between gastroesophageal reflux disease and COPD in UK primary care. Chest 2008, 134:1223-1230.
83. Sasaki T., Nakayama K., Yasuda H., et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. J Am Geriatr Soc 2009, 57:1453-1457.
84. Yohannes A.M., Willgoss T.G., Baldwin R.C., et al. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry 2010, 25:1209-1221.
85. Solano J.P., Gomes B., Higginson I.J. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006, 31:58-69.
86. Maurer J., Rebbapragada V., Borson S., et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 2008, 134:43S-56S.
87. Hanania N.A., Mullerova H., Locantore N.W., et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med 2011, 183:604-611.
88. Laurin C., Lavoie K.L., Bacon S.L., et al. Sex differences in the prevalence of psychiatric disorders and psychological distress in patients with COPD. Chest 2007, 132:148-155.
89. Giardino N.D., Curtis J.L., Andrei A.C., et al. Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study. Respir Res 2010, 11:29.
90. von Leupoldt A., Taube K., Lehmann K., et al. The impact of anxiety and depression on outcomes of pulmonary rehabilitation in patients with COPD. Chest 2011, 140(3):730-736.
91. Eisner M.D., Blanc P.D., Yelin E.H., et al. Influence of anxiety on health outcomes in COPD. Thorax 2010, 65:229-234.
92. de Voogd J.N., Wempe J.B., Koeter G.H., et al. Depressive symptoms as predictors of mortality in patients with COPD. Chest 2009, 135:619-625.
93. Fan V.S., Ramsey S.D., Giardino N.D., et al. Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med 2007, 167:2345-2353.
94. Thakur N., Blanc P.D., Julian L.J., et al. COPD and cognitive impairment: the role of hypoxemia and oxygen therapy. Int J Chron Obstruct Pulmon Dis 2010, 5:263-269.
95. Liesker J.J., Postma D.S., Beukema R.J., et al. Cognitive performance in patients with COPD. Respir Med 2004, 98:351-356.
96. Klein M., Gauggel S., Sachs G., et al. Impact of chronic obstructive pulmonary disease (COPD) on attention functions. Respir Med 2010, 104:52-60.
97. Dodd J.W., Getov S.V., Jones P.W. Cognitive function in COPD. Eur Respir J 2010, 35:913-922.
98. Pereira E.D., Viana C.S., Taunay T.C., et al. Improvement of cognitive function after a three-month pulmonary rehabilitation program for COPD patients. Lung 2011, 189:279-285.
99. Kinsman R.A., Yaroush R.A., Fernandez E., et al. Symptoms and experiences in chronic bronchitis and emphysema. Chest 1983, 83:755-761.
100. Young T., Palta M., Dempsey J., et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993, 328:1230-1235.
101. Simon-Tuval T., Scharf S.M., Maimon N., et al. Determinants of elevated healthcare utilization in patients with COPD. Respir Res 2011, 12:7.
102. Weitzenblum E., Chaouat A., Kessler R., et al. Overlap syndrome: obstructive sleep apnea in patients with chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008, 5:237-241.
103. Mermigkis C., Kopanakis A., Foldvary-Schaefer N., et al. Health-related quality of life in patients with obstructive sleep apnoea and chronic obstructive pulmonary disease (overlap syndrome). Int J Clin Pract 2007, 61:207-211.
104. Criner G.J., Sternberg A.L. National Emphysema Treatment Trial: the major outcomes of lung volume reduction surgery in severe emphysema. Proc Am Thorac Soc 2008, 5:393-405.
105. Calverley P.M., Rabe K.F., Goehring U.M., et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694.